{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:18:46Z","timestamp":1795173526320,"version":"4.10.3"},"reference-count":155,"publisher":"Bentham Science Publishers Ltd.","issue":"27","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>abstract:<\/jats:title>\n<jats:p>Multiple myeloma is a plasma cell neoplasm. The emergence of proteasome\ninhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies has improved\nthe prognosis of multiple myeloma patients. However, some patients are still\ninsensitive to conventional therapy or frequently relapse after remission. Chemotherapy\nbased on proteasome inhibitors or immunomodulatory drugs is ineffective in controlling\nthe progression of relapsed refractory multiple myeloma. No consensus has been\nreached on treating relapsed refractory multiple myeloma to date. Recently chimeric antigen\nreceptor T cells therapy has shown promising results that could achieve rapid remissions\nof patients and improve their prognoses. Additionally, most patients in chimeric\nantigen receptor T cell clinical trials were triple-refractory multiple myeloma patients, indicating\nthat chimeric antigen receptor T cell immunotherapy could overcome drug resistance\nto new drugs. Since single immunotherapies are prone to acquired resistance, combination\nimmunotherapies based on emerging immunotherapies may solve this issue.\nAchieving complete remission and minimal residual disease negative status as soon as\npossible is beneficial to patients. This paper reviewed the main chimeric antigen receptor\nT cell products in relapsed refractory multiple myeloma, and it explained the drug resistance\nmechanism and improvement methods of chimeric antigen receptor T cells therapy.\nThis review summarized the best beneficiaries of chimeric antigen receptor T cell\ntherapy and the salvage treatment of disease recurrence after chimeric antigen receptor\nT cell therapy, providing some ideas for the clinical application of chimeric antigen receptor\nT cells.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673268932230920063933","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T06:23:37Z","timestamp":1696227817000},"page":"4362-4382","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR-T Therapy in Relapsed Refractory Multiple Myeloma"],"prefix":"10.2174","volume":"31","author":[{"given":"Hong","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":true,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","volume":"5","author":"Bailur J.K.","year":"2019","unstructured":"Bailur J.K.; McCachren S.S.; Doxie D.B.; Shrestha M.; Pendleton K.; Nooka A.K.; Neparidze N.; Parker T.L.; Bar N.; Kaufman J.L.; Hofmeister C.C.; Boise L.H.; Lonial S.; Kemp M.L.; Dhodapkar K.M.; Dhodapkar M.V.; Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight  2019,5(11),e127807","journal-title":"JCI Insight"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1038\/bcj.2015.49","volume":"5","author":"Dosani T.","year":"2015","unstructured":"Dosani T.; Carlsten M.; Maric I.; Landgren O.; Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J  2015,5(7),e321","journal-title":"Blood Cancer J"},{"key":"ref=3","first-page":"373","volume":"95","author":"Michels T.C.","year":"2017","unstructured":"Michels T.C.; Petersen K.E.; Multiple myeloma: Diagnosis and treatment. Am Fam Physician  2017,95(6),373-383","journal-title":"Am Fam Physician"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"Greipp P.R.","year":"2005","unstructured":"Greipp P.R.; Miguel J.S.; Durie B.G.M.; Crowley J.J.; Barlogie B.; Blad\u00e9 J.; Boccadoro M.; Child J.A.; Avet-Loiseau H.; Kyle R.A.; Lahuerta J.J.; Ludwig H.; Morgan G.; Powles R.; Shimizu K.; Shustik C.; Sonneveld P.; Tosi P.; Turesson I.; Westin J.; International staging system for multiple myeloma. J Clin Oncol  2005,23(15),3412-3420","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"Rajkumar S.V.","year":"2020","unstructured":"Rajkumar S.V.; Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol  2020,95(5),548-567","journal-title":"Am J Hematol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"Sonneveld P.","year":"2016","unstructured":"Sonneveld P.; Avet-Loiseau H.; Lonial S.; Usmani S.; Siegel D.; Anderson K.C.; Chng W.J.; Moreau P.; Attal M.; Kyle R.A.; Caers J.; Hillengass J.; San Miguel J.; van de Donk N.W.C.J.; Einsele H.; Blad\u00e9 J.; Durie B.G.M.; Goldschmidt H.; Mateos M.V.; Palumbo A.; Orlowski R.; Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood  2016,127(24),2955-2962","journal-title":"Blood"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"Zhang M.","year":"2021","unstructured":"Zhang M.; Zhou L.; Zhao H.; Zhang Y.; Wei G.; Hong R.; Wu W.; Xu H.; Wang L.; Ni F.; Cui J.; Peng S.; Huang C.H.; Chang A.H.; Hu Y.; Huang H.; Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res  2021,27(23),6384-6392","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/07853890.2021.1970218","volume":"53","author":"Zhang L.","year":"2021","unstructured":"Zhang L.; Shen X.; Yu W.; Li J.; Zhang J.; Zhang R.; Li J.; Chen L.; Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med  2021,53(1),1547-1559","journal-title":"Ann Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-020-0307-4","volume":"10","author":"Mina R.","year":"2020","unstructured":"Mina R.; Joseph N.S.; Gay F.; Kastritis E.; Petrucci M.T.; Kaufman J.L.; Montefusco V.; Gavriatopoulou M.; Patriarca F.; Omed\u00e9 P.; Boise L.H.; Roussou M.; Giuliani N.; Oliva S.; Offidani M.; Belotti A.; Jaye D.L.; De Paoli L.; Terpos E.; Lonial S.; Boccadoro M.; Nooka A.K.; Dimopoulos M.A.; Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer J  2020,10(4),40","journal-title":"Blood Cancer J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"Morgan G.J.","year":"2012","unstructured":"Morgan G.J.; Walker B.A.; Davies F.E.; The genetic architecture of multiple myeloma. Nat Rev Cancer  2012,12(5),335-348","journal-title":"Nat Rev Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature09650","volume":"469","author":"Anderson K.","year":"2011","unstructured":"Anderson K.; Lutz C.; van Delft F.W.; Bateman C.M.; Guo Y.; Colman S.M.; Kempski H.; Moorman A.V.; Titley I.; Swansbury J.; Kearney L.; Enver T.; Greaves M.; Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature  2011,469(7330),356-361","journal-title":"Nature"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"Misund K.","year":"2022","unstructured":"Misund K.; Hofste op Bruinink D.; Coward E.; Hoogenboezem R.M.; Rustad E.H.; Sanders M.A.; Rye M.; Sponaas A.M.; van der Holt B.; Zweegman S.; Hovig E.; Meza-Zepeda L.A.; Sundan A.; Myklebost O.; Sonneveld P.; Waage A.; Clonal evolution after treatment pressure in multiple myeloma: Heterogenous genomic aberrations and transcriptomic convergence. Leukemia  2022,36(7),1887-1897","journal-title":"Leukemia"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","volume":"10","author":"Hern\u00e1ndez-Rivas J.\u00c1.","year":"2022","unstructured":"Hern\u00e1ndez-Rivas J.\u00c1.; R\u00edos-Tamayo R.; Encinas C.; Alonso R.; Lahuerta J.J.; The changing landscape of relapsed and\/or refractory multiple myeloma (MM): Fundamentals and controversies. Biomark Res  2022,10(1),1","journal-title":"Biomark Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajh.26379","volume":"97","author":"Lakshman A.","year":"2022","unstructured":"Lakshman A.; Kumar S.K.; Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. Am J Hematol  2022,97(1),99-118","journal-title":"Am J Hematol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"Kegyes D.","year":"2022","unstructured":"Kegyes D.; Constantinescu C.; Vrancken L.; Rasche L.; Gregoire C.; Tigu B.; Gulei D.; Dima D.; Tanase A.; Einsele H.; Ciurea S.; Tomuleasa C.; Caers J.; Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol  2022,15(1),78","journal-title":"J Hematol Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.3390\/cancers14174082","volume":"14","author":"Dima D.","year":"2022","unstructured":"Dima D.; Jiang D.; Singh D.J.; Hasipek M.; Shah H.S.; Ullah F.; Khouri J.; Maciejewski J.P.; Jha B.K.; Multiple myeloma therapy: Emerging trends and challenges. Cancers  2022,14(17),4082","journal-title":"Cancers"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","volume":"18","author":"Costa L.J.","year":"2020","unstructured":"Costa L.J.; Usmani S.Z.; Defining and managing high-risk multiple myeloma: Current concepts. J Natl Compr Canc Netw  2020,18(12),1730-1737","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","volume":"130","author":"Mikkilineni L.","year":"2017","unstructured":"Mikkilineni L.; Kochenderfer J.N.; Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood  2017,130(24),2594-2602","journal-title":"Blood"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"Manier S.","year":"2022","unstructured":"Manier S.; Ingegnere T.; Escure G.; Prodhomme C.; Nudel M.; Mitra S.; Facon T.; Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev  2022,54,100929","journal-title":"Blood Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"Munshi N.C.","year":"2021","unstructured":"Munshi N.C.; Anderson L.D.; Shah N.; Madduri D.; Berdeja J.; Lonial S.; Raje N.; Lin Y.; Siegel D.; Oriol A.; Moreau P.; Yakoub-Agha I.; Delforge M.; Cavo M.; Einsele H.; Goldschmidt H.; Weisel K.; Rambaldi A.; Reece D.; Petrocca F.; Massaro M.; Connarn J.N.; Kaiser S.; Patel P.; Huang L.; Campbell T.B.; Hege K.; San-Miguel J.; Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med  2021,384(8),705-716","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"Berdeja J.G.","year":"2021","unstructured":"Berdeja J.G.; Madduri D.; Usmani S.Z.; Jakubowiak A.; Agha M.; Cohen A.D.; Stewart A.K.; Hari P.; Htut M.; Lesokhin A.; Deol A.; Munshi N.C.; O\u2019Donnell E.; Avigan D.; Singh I.; Zudaire E.; Yeh T.M.; Allred A.J.; Olyslager Y.; Banerjee A.; Jackson C.C.; Goldberg J.D.; Schecter J.M.; Deraedt W.; Zhuang S.H.; Infante J.; Geng D.; Wu X.; Carrasco-Alfonso M.J.; Akram M.; Hossain F.; Rizvi S.; Fan F.; Lin Y.; Martin T.; Jagannath S.; Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study. Lancet  2021,398(10297),314-324","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","volume":"11","author":"Caraccio C.","year":"2020","unstructured":"Caraccio C.; Krishna S.; Phillips D.J.; Sch\u00fcrch C.M.; Bispecific antibodies for multiple myeloma: A review of targets, drugs, clinical trials, and future directions. Front Immunol  2020,11,501","journal-title":"Front Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"Maude S.L.","year":"2018","unstructured":"Maude S.L.; Laetsch T.W.; Buechner J.; Rives S.; Boyer M.; Bittencourt H.; Bader P.; Verneris M.R.; Stefanski H.E.; Myers G.D.; Qayed M.; De Moerloose B.; Hiramatsu H.; Schlis K.; Davis K.L.; Martin P.L.; Nemecek E.R.; Yanik G.A.; Peters C.; Baruchel A.; Boissel N.; Mechinaud F.; Balduzzi A.; Krueger J.; June C.H.; Levine B.L.; Wood P.; Taran T.; Leung M.; Mueller K.T.; Zhang Y.; Sen K.; Lebwohl D.; Pulsipher M.A.; Grupp S.A.; Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med  2018,378(5),439-448","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"Schuster S.J.","year":"2017","unstructured":"Schuster S.J.; Svoboda J.; Chong E.A.; Nasta S.D.; Mato A.R.; Anak \u00d6.; Brogdon J.L.; Pruteanu-Malinici I.; Bhoj V.; Landsburg D.; Wasik M.; Levine B.L.; Lacey S.F.; Melenhorst J.J.; Porter D.L.; June C.H.; Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med  2017,377(26),2545-2554","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","volume":"26","author":"Cohen A.D.","year":"2020","unstructured":"Cohen A.D.; Raje N.; Fowler J.A.; Mezzi K.; Scott E.C.; Dhodapkar M.V.; How to train your T cells: Overcoming immune dysfunction in multiple myeloma. Clin Cancer Res  2020,26(7),1541-1554","journal-title":"Clin Cancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","volume":"3","author":"Holzinger A.","year":"2019","unstructured":"Holzinger A.; Abken H.; CAR T cells: A snapshot on the growing options to design a CAR. HemaSphere  2019,3(1),e172","journal-title":"HemaSphere"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"Sadelain M.","year":"2013","unstructured":"Sadelain M.; Brentjens R.; Rivi\u00e8re I.; The basic principles of chimeric antigen receptor design. Cancer Discov  2013,3(4),388-398","journal-title":"Cancer Discov"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"Savoldo B.","year":"2011","unstructured":"Savoldo B.; Ramos C.A.; Liu E.; Mims M.P.; Keating M.J.; Carrum G.; Kamble R.T.; Bollard C.M.; Gee A.P.; Mei Z.; Liu H.; Grilley B.; Rooney C.M.; Heslop H.E.; Brenner M.K.; Dotti G.; CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients. J Clin Invest  2011,121(5),1822-1826","journal-title":"J Clin Invest"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/mto.2016.14","volume":"3","author":"Abate-Daga D.","year":"2016","unstructured":"Abate-Daga D.; Davila M.L.; CAR models: Next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics  2016,3,16014","journal-title":"Mol Ther Oncolytics"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"Feins S.","year":"2019","unstructured":"Feins S.; Kong W.; Williams E.F.; Milone M.C.; Fraietta J.A.; An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol  2019,94(S1),S3-S9","journal-title":"Am J Hematol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"Maus M.V.","year":"2014","unstructured":"Maus M.V.; Grupp S.A.; Porter D.L.; June C.H.; Antibody-modified T cells: cARs take the front seat for hematologic malignancies. Blood  2014,123(17),2625-2635","journal-title":"Blood"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"Brudno J.N.","year":"2016","unstructured":"Brudno J.N.; Kochenderfer J.N.; Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood  2016,127(26),3321-3330","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"Bonifant C.L.","year":"2016","unstructured":"Bonifant C.L.; Jackson H.J.; Brentjens R.J.; Curran K.J.; Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics  2016,3,16011","journal-title":"Mol Ther Oncolytics"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"Lee D.W.","year":"2014","unstructured":"Lee D.W.; Gardner R.; Porter D.L.; Louis C.U.; Ahmed N.; Jensen M.; Grupp S.A.; Mackall C.L.; Current concepts in the diagnosis and management of cytokine release syndrome. Blood  2014,124(2),188-195","journal-title":"Blood"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"Carpenter R.O.","year":"2013","unstructured":"Carpenter R.O.; Evbuomwan M.O.; Pittaluga S.; Rose J.J.; Raffeld M.; Yang S.; Gress R.E.; Hakim F.T.; Kochenderfer J.N.; B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res  2013,19(8),2048-2060","journal-title":"Clin Cancer Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"Novak A.J.","year":"2004","unstructured":"Novak A.J.; Darce J.R.; Arendt B.K.; Harder B.; Henderson K.; Kindsvogel W.; Gross J.A.; Greipp P.R.; Jelinek D.F.; Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood  2004,103(2),689-694","journal-title":"Blood"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"Moreaux J.","year":"2004","unstructured":"Moreaux J.; Legouffe E.; Jourdan E.; Quittet P.; R\u00e8me T.; Lugagne C.; Moine P.; Rossi J.F.; Klein B.; Tarte K.; BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood  2004,103(8),3148-3157","journal-title":"Blood"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-134324","volume":"136","author":"Lin Y.","year":"2020","unstructured":"Lin Y.; Raje N.S.; Berdeja J.G.; Siegel D.S.; Jagannath S.; Madduri D.; Liedtke M.; Rosenblatt J.; Maus M.V.; Massaro M.; Petrocca F.; Caia A.; Yang Z.; Campbell T.B.; Hege K.; Munshi N.C.; Kochenderfer J.N.; Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: Updated results from phase 1 CRB-401 study. Blood  2020,136(Suppl. 1),26-27","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"Zhao W.H.","year":"2018","unstructured":"Zhao W.H.; Liu J.; Wang B.Y.; Chen Y.X.; Cao X.M.; Yang Y.; Zhang Y.L.; Wang F.X.; Zhang P.Y.; Lei B.; Gu L.F.; Wang J.L.; Yang N.; Zhang R.; Zhang H.; Shen Y.; Bai J.; Xu Y.; Wang X.G.; Zhang R.L.; Wei L.L.; Li Z.F.; Li Z.Z.; Geng Y.; He Q.; Zhuang Q.C.; Fan X.H.; He A.L.; Zhang W.G.; A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol  2018,11(1),141","journal-title":"J Hematol Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"Minnie S.A.","year":"2020","unstructured":"Minnie S.A.; Hill G.R.; Immunotherapy of multiple myeloma. J Clin Invest  2020,130(4),1565-1575","journal-title":"J Clin Invest"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"Park J.H.","year":"2018","unstructured":"Park J.H.; Rivi\u00e8re I.; Gonen M.; Wang X.; S\u00e9n\u00e9chal B.; Curran K.J.; Sauter C.; Wang Y.; Santomasso B.; Mead E.; Roshal M.; Maslak P.; Davila M.; Brentjens R.J.; Sadelain M.; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med  2018,378(5),449-459","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"Garfall A.L.","year":"2015","unstructured":"Garfall A.L.; Maus M.V.; Hwang W.T.; Lacey S.F.; Mahnke Y.D.; Melenhorst J.J.; Zheng Z.; Vogl D.T.; Cohen A.D.; Weiss B.M.; Dengel K.; Kerr N.D.S.; Bagg A.; Levine B.L.; June C.H.; Stadtmauer E.A.; Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med  2015,373(11),1040-1047","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1200\/JCO.2021.39.15_suppl.8014","volume":"39","author":"Jiang H.","year":"2021","unstructured":"Jiang H.; Dong B.; Gao L.; Liu L.; Ge J.; He A.; Li L.; Lu J.; Chen X.; Sersch M.A.; Shen L.; Ye X.; Zhang H.; Zhao Y.; Liu J.; Fu W.; Long-term follow-up results of a multicenter first-in-human study of the dual BCMA\/CD19 Targeted FasT CAR-T GC012F for patients with relapsed\/refractory multiple myeloma. J Clin Oncol  2021,39(15_suppl)(Suppl.),8014","journal-title":"J Clin Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","volume":"20","author":"Chu J.","year":"2014","unstructured":"Chu J.; He S.; Deng Y.; Zhang J.; Peng Y.; Hughes T.; Yi L.; Kwon C.H.; Wang Q.E.; Devine S.M.; He X.; Bai X.F.; Hofmeister C.C.; Yu J.; Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res  2014,20(15),3989-4000","journal-title":"Clin Cancer Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","volume":"29","author":"Cannons J.L.","year":"2011","unstructured":"Cannons J.L.; Tangye S.G.; Schwartzberg P.L.; SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol  2011,29(1),665-705","journal-title":"Annu Rev Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","volume":"2","author":"Richardson P.G.","year":"2015","unstructured":"Richardson P.G.; Jagannath S.; Moreau P.; Jakubowiak A.J.; Raab M.S.; Facon T.; Vij R.; White D.; Reece D.E.; Benboubker L.; Zonder J.; Tsao L.C.; Anderson K.C.; Bleickardt E.; Singhal A.K.; Lonial S.; Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b\u20132 dose-escalation study. Lancet Haematol  2015,2(12),e516-e527","journal-title":"Lancet Haematol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","volume":"121","author":"O\u2019Connell F.P.","year":"2004","unstructured":"O\u2019Connell F.P.; Pinkus J.L.; Pinkus G.S.; CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol  2004,121(2),254-263","journal-title":"Am J Clin Pathol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/hematology.2019000370","volume":"2019","author":"Sidana S.","year":"2019","unstructured":"Sidana S.; Shah N.; CAR T-cell therapy: Is it prime time in myeloma? Hematology (Am Soc Hematol Educ Program)  2019,2019(1),260-265","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"Mei H.","year":"2021","unstructured":"Mei H.; Li C.; Jiang H.; Zhao X.; Huang Z.; Jin D.; Guo T.; Kou H.; Liu L.; Tang L.; Yin P.; Wang Z.; Ai L.; Ke S.; Xia Y.; Deng J.; Chen L.; Cai L.; Sun C.; Xia L.; Hua G.; Hu Y.; A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol  2021,14(1),161","journal-title":"J Hematol Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Yan Z.","year":"2019","unstructured":"Yan Z.; Cao J.; Cheng H.; Qiao J.; Zhang H.; Wang Y.; Shi M.; Lan J.; Fei X.; Jin L.; Jing G.; Sang W.; Zhu F.; Chen W.; Wu Q.; Yao Y.; Wang G.; Zhao J.; Zheng J.; Li Z.; Xu K.; A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial. Lancet Haematol  2019,6(10),e521-e529","journal-title":"Lancet Haematol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"Shi X.","year":"2022","unstructured":"Shi X.; Yan L.; Shang J.; Kang L.; Yan Z.; Jin S.; Zhu M.; Chang H.; Gong F.; Zhou J.; Chen G.; Pan J.; Liu D.; Zhu X.; Tang F.; Liu M.; Liu W.; Yao F.; Yu L.; Wu D.; Fu C.; Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol  2022,97(5),537-547","journal-title":"Am J Hematol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-140727","volume":"136","author":"Chen W.","year":"2020","unstructured":"Chen W.; Fu C.; Cai Z.; Li Z.; Wang H.; Yan L.; Wu Y.; Shi X.; Gao W.; Yan S.; Wang W.; Han X.; Zheng G.; Wen Y.; Xiao J.; Wang H.; Ma H.; Results from lummicar-1: A phase 1 study of fully human B-cell maturation antigen-specific CAR T Cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma. Blood  2020,136(Suppl. 1),49-50","journal-title":"Blood"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-139802","volume":"136","author":"Kumar S.K.","year":"2020","unstructured":"Kumar S.K.; Baz R.C.; Orlowski R.Z.; Anderson L.D.; Ma H.; Shrewsbury A.; Croghan K.A.; Bilgi M.; Kansagra A.; Kapoor P.; Li Z.; Brayer J.; Results from lummicar-2: A phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma. Blood  2020,136(Suppl. 1),28-29","journal-title":"Blood"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","volume":"136","author":"Costello C.L.","year":"2020","unstructured":"Costello C.L.; Cohen A.D.; Patel K.K.; Ali S.S.; Berdeja J.G.; Shah N.; Ganguly S.; Kocoglu M.H.; Abedi M.; Ostertag E.M.; Martin C.E.; Ghoddussi M.; Shedlock D.J.; McCaigue J.; Namini H.; Yalamanchili S.; Spear M.A.; Gregory T.K.; Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies. Blood  2020,136(Suppl. 1),29-30","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","volume":"136","author":"Alsina M.","year":"2020","unstructured":"Alsina M.; Shah N.; Raje N.S.; Jagannath S.; Madduri D.; Kaufman J.L.; Siegel D.S.; Munshi N.C.; Rosenblatt J.; Lin Y.; Jakubowiak A.; Jasielec J.; Timm A.; Turka A.; Mao P.; Martin N.; Campbell T.B.; Hege K.; Bitter H.; Petrocca F.; Berdeja J.G.; Updated results from the phase I CRB-402 study of anti-bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes. Blood  2020,136(Suppl. 1),25-26","journal-title":"Blood"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2021-145572","volume":"138","author":"Mailankody S.","year":"2021","unstructured":"Mailankody S.; Liedtke M.; Sidana S.; Matous J.V.; Chhabra S.; Oluwole O.O.; Malik S.A.; Kumar S.; Nath R.; Anwer F.; Cruz J.C.; Jagannath S.; Htut M.; Raje N.S.; Siegel D.S.; Karski E.E.; Lovelace W.; Lourbakos A.; Ponnathapura Nandakumar S.; Balakumaran A.; Hari P.; Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma. Blood  2021,138(Suppl. 1),651","journal-title":"Blood"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cyto.b.21092","volume":"84B","author":"Quarona V.","year":"2013","unstructured":"Quarona V.; Zaccarello G.; Chillemi A.; Brunetti E.; Singh V.K.; Ferrero E.; Funaro A.; Horenstein A.L.; Malavasi F.; CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry B Clin Cytom  2013,84B(4),207-217","journal-title":"Cytometry B Clin Cytom"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"Drent E.","year":"2017","unstructured":"Drent E.; Themeli M.; Poels R.; de Jong-Korlaar R.; Yuan H.; de Bruijn J.; Martens A.C.M.; Zweegman S.; van de Donk N.W.C.J.; Groen R.W.J.; Lokhorst H.M.; Mutis T.; A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther  2017,25(8),1946-1958","journal-title":"Mol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"Straathof K.C.","year":"2005","unstructured":"Straathof K.C.; Pul\u00e8 M.A.; Yotnda P.; Dotti G.; Vanin E.F.; Brenner M.K.; Heslop H.E.; Spencer D.M.; Rooney C.M.; An inducible caspase 9 safety switch for T-cell therapy. Blood  2005,105(11),4247-4254","journal-title":"Blood"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"Attal M.","year":"2019","unstructured":"Attal M.; Richardson P.G.; Rajkumar S.V.; San-Miguel J.; Beksac M.; Spicka I.; Leleu X.; Schjesvold F.; Moreau P.; Dimopoulos M.A.; Huang J.S.Y.; Minarik J.; Cavo M.; Prince H.M.; Mac\u00e9 S.; Corzo K.P.; Campana F.; Le-Guennec S.; Dubin F.; Anderson K.C.; Attal M.; Richardson P.G.; Rajkumar V.; San-Miguel J.; Beksac M.; Spicka I.; Leleu X.; Schjesvold F.; Moreau P.; Dimopoulos M.A.; Huang J.S-Y.; Minarik J.; Cavo M.; Prince H.M.; Mac\u00e9 S.; Corzo K.P.; Campana F.; Le-Guennec S.; Dubin F.; Anderson K.C.; Harrison S.; Janowski W.; Kerridge I.; Spencer A.; Delforge M.; Fostier K.; Vlummens P.; Wu K.L.; Leblanc R.; Pavic M.; Sebag M.; Hajek R.; Maisnar V.; Pour L.; Gregersen H.; Benbouker L.; Caillot D.; Escoffre-Barbe M.; Facon T.; Frenzel L.; Hulin C.; Karlin L.; Kolb B.; Pegourie B.; Perrot A.; Tiab M.; Vincent L.; Niederwieser D.; Anagnostopoulos A.; Delimpasi S.; Kyrtsonis M-C.; Symeonidis A.; Illes A.; Mikala G.; Nagy Z.; Bringen S.; Corradini P.; Fabio C.; Lemoli R.; Liberati A.; Nozzoli C.; Zambello R.; Iida S.; Ikeda T.; Iyama S.; Matsumoto M.; Shimazaki C.; Sunami K.; Suzuki K.; Uchiyama M.; Koh Y.; Kim K.; Lee J.H.; Min C-K.; Blacklock H.; Goodman H.; Neylon A.; Simpson D.; Grosicki S.; Jurczyszyn A.; Walter-Croneck A.; Warzocha K.; Araujo L.; Moreira C.; Doronin V.; Mendeleeva L.; Vorobyev V.; Vranovsky A.; Alegre A.; Gironella M.; Gonzalez Perez M.S.; Montes C.; Ocio E.; Rodriguez P.; Hardling M.; Lauri B.; Wang M-C.; Yeh S-P.; Arat M.; Demirkan F.; Gulbas Z.; Besisik S.K.; Karadogan I.; Tuglular T.; Unal A.; Vural F.; Sive J.; Streetly M.; Yong K.; Tache J.; Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet  2019,394(10214),2096-2107","journal-title":"Lancet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"Palumbo A.","year":"2016","unstructured":"Palumbo A.; Chanan-Khan A.; Weisel K.; Nooka A.K.; Masszi T.; Beksac M.; Spicka I.; Hungria V.; Munder M.; Mateos M.V.; Mark T.M.; Qi M.; Schecter J.; Amin H.; Qin X.; Deraedt W.; Ahmadi T.; Spencer A.; Sonneveld P.; Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med  2016,375(8),754-766","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-019-01080-6","volume":"79","author":"Syed Y.Y.","year":"2019","unstructured":"Syed Y.Y.; Daratumumab: A review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma. Drugs  2019,79(4),447-454","journal-title":"Drugs"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","volume":"101","author":"Drent E.","year":"2016","unstructured":"Drent E.; Groen R.W.J.; Noort W.A.; Themeli M.; Lammerts van Bueren J.J.; Parren P.W.H.I.; Kuball J.; Sebestyen Z.; Yuan H.; de Bruijn J.; van de Donk N.W.C.J.; Martens A.C.M.; Lokhorst H.M.; Mutis T.; Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica  2016,101(5),616-625","journal-title":"Haematologica"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"Smith E.L.","year":"2019","unstructured":"Smith E.L.; Harrington K.; Staehr M.; Masakayan R.; Jones J.; Long T.J.; Ng K.Y.; Ghoddusi M.; Purdon T.J.; Wang X.; Do T.; Pham M.T.; Brown J.M.; De Larrea C.F.; Olson E.; Peguero E.; Wang P.; Liu H.; Xu Y.; Garrett-Thomson S.C.; Almo S.C.; Wendel H.G.; Riviere I.; Liu C.; Sather B.; Brentjens R.J.; GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med  2019,11(485),eaau7746","journal-title":"Sci Transl Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"Atamaniuk J.","year":"2012","unstructured":"Atamaniuk J.; Gleiss A.; Porpaczy E.; Kainz B.; Grunt T.W.; Raderer M.; Hilgarth B.; Drach J.; Ludwig H.; Gisslinger H.; Jaeger U.; Gaiger A.; Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest  2012,42(9),953-960","journal-title":"Eur J Clin Invest"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","volume":"26","author":"Smith E.L.","year":"2018","unstructured":"Smith E.L.; Staehr M.; Masakayan R.; Tatake I.J.; Purdon T.J.; Wang X.; Wang P.; Liu H.; Xu Y.; Garrett-Thomson S.C.; Almo S.C.; Riviere I.; Liu C.; Brentjens R.J.; Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther  2018,26(6),1447-1456","journal-title":"Mol Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","volume":"34","author":"Gagelmann N.","year":"2020","unstructured":"Gagelmann N.; Riecken K.; Wolschke C.; Berger C.; Ayuk F.A.; Fehse B.; Kr\u00f6ger N.; Development of CAR-T cell therapies for multiple myeloma. Leukemia  2020,34(9),2317-2332","journal-title":"Leukemia"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"Mailankody S.","year":"2022","unstructured":"Mailankody S.; Devlin S.M.; Landa J.; Nath K.; Diamonte C.; Carstens E.J.; Russo D.; Auclair R.; Fitzgerald L.; Cadzin B.; Wang X.; Sikder D.; Senechal B.; Bermudez V.P.; Purdon T.J.; Hosszu K.; McAvoy D.P.; Farzana T.; Mead E.; Wilcox J.A.; Santomasso B.D.; Shah G.L.; Shah U.A.; Korde N.; Lesokhin A.; Tan C.R.; Hultcrantz M.; Hassoun H.; Roshal M.; Sen F.; Dogan A.; Landgren O.; Giralt S.A.; Park J.H.; Usmani S.Z.; Rivi\u00e8re I.; Brentjens R.J.; Smith E.L.; GPRC5D-targeted CAR T cells for myeloma. N Engl J Med  2022,387(13),1196-1206","journal-title":"N Engl J Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"Zhang M.","year":"2023","unstructured":"Zhang M.; Wei G.; Zhou L.; Zhou J.; Chen S.; Zhang W.; Wang D.; Luo X.; Cui J.; Huang S.; Fu S.; Zhou X.; Tang Y.; Ding X.; Kuang J.; He X.P.; Hu Y.; Huang H.; GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol  2023,10(2),e107-e116","journal-title":"Lancet Haematol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal S.","year":"2022","unstructured":"Bal S.; Kocoglu M.H.; Nadeem O.; Htut M.; Gregory T.; Anderson L.D.; Costa L.J.; Buchholz T.J.; Ziyad S.; Li M.; Chen Y.; Kaeding A.J.; Burgess M.R.; Hege K.; Berdeja J.; Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and\/or refractory (R\/R) multiple myeloma (MM): First results from a phase 1, multicenter, open-label study. Blood  2022,140(Suppl. 1),883-885","journal-title":"Blood"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"Raje N.","year":"2019","unstructured":"Raje N.; Berdeja J.; Lin Y.; Siegel D.; Jagannath S.; Madduri D.; Liedtke M.; Rosenblatt J.; Maus M.V.; Turka A.; Lam L.P.; Morgan R.A.; Friedman K.; Massaro M.; Wang J.; Russotti G.; Yang Z.; Campbell T.; Hege K.; Petrocca F.; Quigley M.T.; Munshi N.; Kochenderfer J.N.; Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med  2019,380(18),1726-1737","journal-title":"N Engl J Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"Samur M.K.","year":"2021","unstructured":"Samur M.K.; Fulciniti M.; Aktas Samur A.; Bazarbachi A.H.; Tai Y.T.; Prabhala R.; Alonso A.; Sperling A.S.; Campbell T.; Petrocca F.; Hege K.; Kaiser S.; Loiseau H.A.; Anderson K.C.; Munshi N.C.; Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun  2021,12(1),868","journal-title":"Nat Commun"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","volume":"132","author":"Li C.","year":"2018","unstructured":"Li C.; Wang Q.; Zhu H.; Mao X.; Wang Y.; Zhang Y.; Zhou J.; T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies. Blood  2018,132(Suppl. 1),1013","journal-title":"Blood"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"Pont M.J.","year":"2019","unstructured":"Pont M.J.; Hill T.; Cole G.O.; Abbott J.J.; Kelliher J.; Salter A.I.; Hudecek M.; Comstock M.L.; Rajan A.; Patel B.K.R.; Voutsinas J.M.; Wu Q.; Liu L.; Cowan A.J.; Wood B.L.; Green D.J.; Riddell S.R.; \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood  2019,134(19),1585-1597","journal-title":"Blood"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"Green D.J.","year":"2018","unstructured":"Green D.J.; Pont M.; Sather B.D.; Cowan A.J.; Turtle C.J.; Till B.G.; Nagengast A.M.; Libby E.N.; Becker P.S.; Coffey D.G.; Tuazon S.A.; Wood B.; Blake M.; Works M.; Thompson B.S.; Gooley T.; Appelbaum F.R.; Maloney D.G.; Riddell S.R.; Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood  2018,132(Suppl. 1),1011","journal-title":"Blood"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2019-122907","volume":"134","author":"Chen C.I.","year":"2019","unstructured":"Chen C.I.; Bahlis N.; Gasparetto C.; Tuchman S.A.; Lipe B.C.; Baljevic M.; Kotb R.; Sutherland H.J.; Bensinger W.I.; Sebag M.; Leblanc R.; Venner C.P.; Schiller G.J.; Lentzsch S.; Callander N.S.; Sheehan H.; Chai Y.; Kai K.; Shah J.; Shacham S.; Kauffman M.G.; White D.J.; Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood  2019,134(Suppl. 1),141","journal-title":"Blood"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"Cohen A.D.","year":"2019","unstructured":"Cohen A.D.; Garfall A.L.; Stadtmauer E.A.; Melenhorst J.J.; Lacey S.F.; Lancaster E.; Vogl D.T.; Weiss B.M.; Dengel K.; Nelson A.; Plesa G.; Chen F.; Davis M.M.; Hwang W.T.; Young R.M.; Brogdon J.L.; Isaacs R.; Pruteanu-Malinici I.; Siegel D.L.; Levine B.L.; June C.H.; Milone M.C.; B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Invest  2019,129(6),2210-2221","journal-title":"J Clin Invest"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"Brudno J.N.","year":"2018","unstructured":"Brudno J.N.; Maric I.; Hartman S.D.; Rose J.J.; Wang M.; Lam N.; Stetler-Stevenson M.; Salem D.; Yuan C.; Pavletic S.; Kanakry J.A.; Ali S.A.; Mikkilineni L.; Feldman S.A.; Stroncek D.F.; Hansen B.G.; Lawrence J.; Patel R.; Hakim F.; Gress R.E.; Kochenderfer J.N.; T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol  2018,36(22),2267-2280","journal-title":"J Clin Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood-2019-122513","volume":"134","author":"Wang M.","year":"2019","unstructured":"Wang M.; Pruteanu I.; Cohen A.D.; Garfall A.L.; Milone M.C.; Tian L.; Gonzalez V.E.; Gill S.; Frey N.V.; Barrett D.M.; Ruella M.; Lacey S.F.; Svoboda J.; Chong E.A.; Fraietta J.A.; Davis M.; Nasta S.D.; Levine B.L.; Siegel D.L.; Maude S.L.; Schuster S.J.; Stadtmauer E.A.; Grupp S.; Porter D.L.; June C.H.; Melenhorst J.J.; Identification and validation of predictive biomarkers to CD19- and BCMA-specific CAR T-cell responses in CAR T-cell precursors. Blood  2019,134(Suppl. 1),622","journal-title":"Blood"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"Leblay N.","year":"2020","unstructured":"Leblay N.; Maity R.; Barakat E.; McCulloch S.; Duggan P.; Jimenez-Zepeda V.; Bahlis N.J.; Neri P.; Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood  2020,136(Suppl. 1),11-12","journal-title":"Blood"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"Sommermeyer D.","year":"2016","unstructured":"Sommermeyer D.; Hudecek M.; Kosasih P.L.; Gogishvili T.; Maloney D.G.; Turtle C.J.; Riddell S.R.; Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia  2016,30(2),492-500","journal-title":"Leukemia"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"Garfall A.L.","year":"2019","unstructured":"Garfall A.L.; Dancy E.K.; Cohen A.D.; Hwang W.T.; Fraietta J.A.; Davis M.M.; Levine B.L.; Siegel D.L.; Stadtmauer E.A.; Vogl D.T.; Waxman A.; Rapoport A.P.; Milone M.C.; June C.H.; Melenhorst J.J.; T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv  2019,3(19),2812-2815","journal-title":"Blood Adv"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1084\/jem.20031030","volume":"198","author":"Dhodapkar M.V.","year":"2003","unstructured":"Dhodapkar M.V.; Krasovsky J.; Osman K.; Geller M.D.; Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med  2003,198(11),1753-1757","journal-title":"J Exp Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"Zelle-Rieser C.","year":"2016","unstructured":"Zelle-Rieser C.; Thangavadivel S.; Biedermann R.; Brunner A.; Stoitzner P.; Willenbacher E.; Greil R.; J\u00f6hrer K.; T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol  2016,9(1),116","journal-title":"J Hematol Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"Long A.H.","year":"2015","unstructured":"Long A.H.; Haso W.M.; Shern J.F.; Wanhainen K.M.; Murgai M.; Ingaramo M.; Smith J.P.; Walker A.J.; Kohler M.E.; Venkateshwara V.R.; Kaplan R.N.; Patterson G.H.; Fry T.J.; Orentas R.J.; Mackall C.L.; 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med  2015,21(6),581-590","journal-title":"Nat Med"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718822660","volume":"10","author":"Franssen L.E.","year":"2019","unstructured":"Franssen L.E.; Mutis T.; Lokhorst H.M.; van de Donk N.W.C.J.; Immunotherapy in myeloma: How far have we come? Ther Adv Hematol  2019,10","journal-title":"Ther Adv Hematol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","volume":"13","author":"Salik B.","year":"2020","unstructured":"Salik B.; Smyth M.J.; Nakamura K.; Targeting immune checkpoints in hematological malignancies. J Hematol Oncol  2020,13(1),111","journal-title":"J Hematol Oncol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"Vignali D.A.A.","year":"2008","unstructured":"Vignali D.A.A.; Collison L.W.; Workman C.J.; How regulatory T cells work. Nat Rev Immunol  2008,8(7),523-532","journal-title":"Nat Rev Immunol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"Rosser E.C.","year":"2015","unstructured":"Rosser E.C.; Mauri C.; Regulatory B cells: Origin, phenotype, and function. Immunity  2015,42(4),607-612","journal-title":"Immunity"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"Zah E.","year":"2020","unstructured":"Zah E.; Nam E.; Bhuvan V.; Tran U.; Ji B.Y.; Gosliner S.B.; Wang X.; Brown C.E.; Chen Y.Y.; Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun  2020,11(1),2283","journal-title":"Nat Commun"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","volume":"116","author":"Park J.J.","year":"2010","unstructured":"Park J.J.; Omiya R.; Matsumura Y.; Sakoda Y.; Kuramasu A.; Augustine M.M.; Yao S.; Tsushima F.; Narazaki H.; Anand S.; Liu Y.; Strome S.E.; Chen L.; Tamada K.; B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood  2010,116(8),1291-1298","journal-title":"Blood"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","volume":"110","author":"Liu J.","year":"2007","unstructured":"Liu J.; Hamrouni A.; Wolowiec D.; Coiteux V.; Kuliczkowski K.; Hetuin D.; Saudemont A.; Quesnel B.; Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood  2007,110(1),296-304","journal-title":"Blood"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","volume":"32","author":"Chen K.H.","year":"2018","unstructured":"Chen K.H.; Wada M.; Pinz K.G.; Liu H.; Shuai X.; Chen X.; Yan L.E.; Petrov J.C.; Salman H.; Senzel L.; Leung E.L.H.; Jiang X.; Ma Y.; A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia  2018,32(2),402-412","journal-title":"Leukemia"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","volume":"9","author":"Shah N.N.","year":"2019","unstructured":"Shah N.N.; Maatman T.; Hari P.; Johnson B.; Multi targeted CAR-T cell therapies for b-cell malignancies. Front Oncol  2019,9,146","journal-title":"Front Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"Mailankody S.","year":"2020","unstructured":"Mailankody S.; Jakubowiak A.J.; Htut M.; Costa L.J.; Lee K.; Ganguly S.; Kaufman J.L.; Siegel D.S.D.; Bensinger W.; Cota M.; Doerr T.; DeVries T.; Wong S.W.K.; Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011). J Clin Oncol  2020,38(15_suppl)(Suppl.),8504","journal-title":"J Clin Oncol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2019.37.15_suppl.8013","volume":"37","year":"2019","unstructured":"Li C, Zhou J, Wang J, Hu G, Du A, Zhou X, Meng L, Hong Z, Chen L, Mao X. Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol  2019,37(15)(Suppl.),8013","journal-title":"J Clin Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-138839","volume":"136","author":"Mikkilineni L.","year":"2020","unstructured":"Mikkilineni L.; Manasanch E.E.; Vanasse D.; Brudno J.N.; Mann J.; Sherry R.; Goff S.L.; Yang J.C.; Lam N.; Maric I.; Stetler-Stevenson M.; Wang H.W.; Yuan C.M.; Stroncek D.F.; Highfill S.L.; Fellowes V.; Ganadan M.; Patel R.; Rosenberg S.A.; Kochenderfer J.N.; Deep and durable remissions of relapsed multiple myeloma on a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) with a fully-human heavy-chain-only antigen recognition domain. Blood  2020,136(Suppl. 1),50-51","journal-title":"Blood"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41434-020-0138-8","volume":"28","author":"Ivics Z.","year":"2021","unstructured":"Ivics Z.; Potent CAR-T cells engineered with sleeping beauty transposon vectors display a central memory phenotype. Gene Ther  2021,28(1-2),3-5","journal-title":"Gene Ther"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"McLellan A.D.","year":"2019","unstructured":"McLellan A.D.; Ali Hosseini Rad S.M.; Chimeric antigen receptor T cell persistence and memory cell formation. Immunol Cell Biol  2019,97(7),664-674","journal-title":"Immunol Cell Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","volume":"132","author":"Shah N.","year":"2018","unstructured":"Shah N.; Alsina M.; Siegel D.S.; Jagannath S.; Madduri D.; Kaufman J.L.; Turka A.; Lam L.P.; Massaro M.; Hege K.; Petrocca F.; Berdeja J.G.; Raje N.; Initial results from a phase 1 clinical study of bb21217, a next-generation anti bcma CAR T therapy. Blood  2018,132(Suppl. 1),488","journal-title":"Blood"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"609421","DOI":"10.3389\/fimmu.2021.609421","volume":"12","author":"Duan D.","year":"2021","unstructured":"Duan D.; Wang K.; Wei C.; Feng D.; Liu Y.; He Q.; Xu X.; Wang C.; Zhao S.; Lv L.; Long J.; Lin D.; Zhao A.; Fang B.; Jiang J.; Tang S.; Gao J.; The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol  2021,12,609421","journal-title":"Front Immunol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"Hu B.","year":"2017","unstructured":"Hu B.; Ren J.; Luo Y.; Keith B.; Young R.M.; Scholler J.; Zhao Y.; June C.H.; Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep  2017,20(13),3025-3033","journal-title":"Cell Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e20192203","DOI":"10.1084\/jem.20192203","volume":"218","author":"Lanitis E.","year":"2021","unstructured":"Lanitis E.; Rota G.; Kosti P.; Ronet C.; Spill A.; Seijo B.; Romero P.; Dangaj D.; Coukos G.; Irving M.; Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med  2021,218(2),e20192203","journal-title":"J Exp Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"Das R.K.","year":"2019","unstructured":"Das R.K.; Vernau L.; Grupp S.A.; Barrett D.M.; Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov  2019,9(4),492-499","journal-title":"Cancer Discov"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","volume":"132","author":"Dancy E.","year":"2018","unstructured":"Dancy E.; Garfall A.L.; Cohen A.D.; Fraietta J.A.; Davis M.; Levine B.L.; Siegel D.L.; Stadtmauer E.A.; Vogl D.T.; Waxman A.; Rapoport A.P.; Milone M.C.; June C.H.; Melenhorst J.J.; Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. Blood  2018,132(Suppl. 1),1886","journal-title":"Blood"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17805","volume":"196","author":"Swan D.","year":"2022","unstructured":"Swan D.; Routledge D.; Harrison S.; The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies. Br J Haematol  2022,196(3),488-506","journal-title":"Br J Haematol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-19-0267","volume":"26","author":"Kwon M.","year":"2020","unstructured":"Kwon M.; Kim C.G.; Lee H.; Cho H.; Kim Y.; Lee E.C.; Choi S.J.; Park J.; Seo I.H.; Bogen B.; Song I.C.; Jo D.Y.; Kim J.S.; Park S.H.; Choi I.; Choi Y.S.; Shin E.C.; PD-1 blockade reinvigorates bone marrow CD8 T cells from patients with multiple myeloma in the presence of TGF\u03b2 inhibitors. Clin Cancer Res  2020,26(7),1644-1655","journal-title":"Clin Cancer Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"Benson D.M.","year":"2010","unstructured":"Benson D.M.; Bakan C.E.; Mishra A.; Hofmeister C.C.; Efebera Y.; Becknell B.; Baiocchi R.A.; Zhang J.; Yu J.; Smith M.K.; Greenfield C.N.; Porcu P.; Devine S.M.; Rotem-Yehudar R.; Lozanski G.; Byrd J.C.; Caligiuri M.A.; The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody. Blood  2010,116(13),2286-2294","journal-title":"Blood"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1158\/0008-5472.CAN-15-3352","volume":"76","author":"Menger L.","year":"2016","unstructured":"Menger L.; Sledzinska A.; Bergerhoff K.; Vargas F.A.; Smith J.; Poirot L.; Pule M.; Herrero J.; Peggs K.S.; Quezada S.A.; TALEN-Mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. Cancer Res  2016,76(8),2087-2093","journal-title":"Cancer Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"Rupp L.J.","year":"2017","unstructured":"Rupp L.J.; Schumann K.; Roybal K.T.; Gate R.E.; Ye C.J.; Lim W.A.; Marson A.; CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep  2017,7(1),737","journal-title":"Sci Rep"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"Stadtmauer E.A.","year":"2020","unstructured":"Stadtmauer E.A.; Fraietta J.A.; Davis M.M.; Cohen A.D.; Weber K.L.; Lancaster E.; Mangan P.A.; Kulikovskaya I.; Gupta M.; Chen F.; Tian L.; Gonzalez V.E.; Xu J.; Jung I.; Melenhorst J.J.; Plesa G.; Shea J.; Matlawski T.; Cervini A.; Gaymon A.L.; Desjardins S.; Lamontagne A.; Salas-Mckee J.; Fesnak A.; Siegel D.L.; Levine B.L.; Jadlowsky J.K.; Young R.M.; Chew A.; Hwang W.T.; Hexner E.O.; Carreno B.M.; Nobles C.L.; Bushman F.D.; Parker K.R.; Qi Y.; Satpathy A.T.; Chang H.Y.; Zhao Y.; Lacey S.F.; June C.H.; CRISPR-engineered T cells in patients with refractory cancer. Science  2020,367(6481),eaba7365","journal-title":"Science"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"Liu X.","year":"2017","unstructured":"Liu X.; Zhang Y.; Cheng C.; Cheng A.W.; Zhang X.; Li N.; Xia C.; Wei X.; Liu X.; Wang H.; CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res  2017,27(1),154-157","journal-title":"Cell Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","volume":"8","author":"Ren J.","year":"2017","unstructured":"Ren J.; Zhang X.; Liu X.; Fang C.; Jiang S.; June C.H.; Zhao Y.; A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget  2017,8(10),17002-17011","journal-title":"Oncotarget"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1019548","DOI":"10.3389\/fimmu.2022.1019548","volume":"13","author":"Li H.","year":"2022","unstructured":"Li H.; Zhao L.; Sun Z.; Yao Y.; Li L.; Wang J.; Hua T.; Ji S.; Wang S.; Cheng H.; Shi M.; Li Z.; Zeng L.; Wu Q.; Qiao J.; Chen C.; Zheng J.; Cao J.; Xu K.; Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front Immunol  2022,13,1019548","journal-title":"Front Immunol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"Hanamura I.","year":"2006","unstructured":"Hanamura I.; Stewart J.P.; Huang Y.; Zhan F.; Santra M.; Sawyer J.R.; Hollmig K.; Zangarri M.; Pineda-Roman M.; van Rhee F.; Cavallo F.; Burington B.; Crowley J.; Tricot G.; Barlogie B.; Shaughnessy J.D.; Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood  2006,108(5),1724-1732","journal-title":"Blood"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"Xiong W.","year":"2008","unstructured":"Xiong W.; Wu X.; Starnes S.; Johnson S.K.; Haessler J.; Wang S.; Chen L.; Barlogie B.; Shaughnessy J.D.; Zhan F.; An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood  2008,112(10),4235-4246","journal-title":"Blood"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","volume":"106","author":"Gertz M.A.","year":"2005","unstructured":"Gertz M.A.; Lacy M.Q.; Dispenzieri A.; Greipp P.R.; Litzow M.R.; Henderson K.J.; Van Wier S.A.; Ahmann G.J.; Fonseca R.; Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood  2005,106(8),2837-2840","journal-title":"Blood"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.7150\/ijms.46811","volume":"18","author":"Yang Q.","year":"2021","unstructured":"Yang Q.; Li X.; Zhang F.; Yang Q.; Zhou W.; Liu J.; Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis. Int J Med Sci  2021,18(8),1786-1797","journal-title":"Int J Med Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","volume":"104","author":"Gagelmann N.","year":"2020","unstructured":"Gagelmann N.; Ayuk F.; Atanackovic D.; Kr\u00f6ger N.; B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. Eur J Haematol  2020,104(4),318-327","journal-title":"Eur J Haematol"},{"key":"ref=120","author":"Van Oekelen O.","year":"2022","unstructured":"Van Oekelen O.; Nath K.; Mouhieddine T.H.; Farzana T.; Aleman A.; Melnekoff D.T.; Ghodke-Puranik Y.; Shah G.L.; Lesokhin A.M.; Giralt S.A.; Thibaud S.; Rossi A.; Rodriguez C.; Sanchez L.; Richter J.; Richard S.; Cho H.J.; Chari A.; Usmani S.Z.; Jagannath S.; Shah U.A.; Mailankody S.; Parekh S.; Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy. Blood  2022","journal-title":"Blood"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1182\/blood.2020009206","volume":"137","author":"Casucci M.","year":"2021","unstructured":"Casucci M.; Ciceri F.; A second CD19 CAR T-cell infusion: Yes or no? Blood  2021,137(3),284-286","journal-title":"Blood"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"Gauthier J.","year":"2021","unstructured":"Gauthier J.; Bezerra E.D.; Hirayama A.V.; Fiorenza S.; Sheih A.; Chou C.K.; Kimble E.L.; Pender B.S.; Hawkins R.M.; Vakil A.; Phi T.D.; Steinmetz R.N.; Jamieson A.W.; Bar M.; Cassaday R.D.; Chapuis A.G.; Cowan A.J.; Green D.J.; Kiem H.P.; Milano F.; Shadman M.; Till B.G.; Riddell S.R.; Maloney D.G.; Turtle C.J.; Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood  2021,137(3),323-335","journal-title":"Blood"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"Fern\u00e1ndez de Larrea C.","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C.; Staehr M.; Lopez A.V.; Ng K.Y.; Chen Y.; Godfrey W.D.; Purdon T.J.; Ponomarev V.; Wendel H.G.; Brentjens R.J.; Smith E.L.; Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent bcma escape\u2013driven relapse in multiple myeloma. Blood Cancer Discov  2020,1(2),146-154","journal-title":"Blood Cancer Discov"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","volume":"134","author":"Popat R.","year":"2019","unstructured":"Popat R.; Zweegman S.; Cavet J.; Yong K.; Lee L.; Faulkner J.; Kotsopoulou E.; Al-Hajj M.; Thomas S.; Cordoba S.P.; Pule M.; Cerec V.; Peddareddigari V.G.R.; Khokhar N.Z.; Menne T.F.; Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM). Blood  2019,134(Suppl. 1),3112","journal-title":"Blood"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"100678","DOI":"10.1016\/j.blre.2020.100678","volume":"44","author":"Tanaka J.","year":"2020","unstructured":"Tanaka J.; Miller J.S.; Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Rev  2020,44,100678","journal-title":"Blood Rev"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"Leivas A.","year":"2021","unstructured":"Leivas A.; Valeri A.; C\u00f3rdoba L.; Garc\u00eda-Ortiz A.; Ortiz A.; S\u00e1nchez-Vega L.; Gra\u00f1a-Castro O.; Fern\u00e1ndez L.; Carre\u00f1o-Tarragona G.; P\u00e9rez M.; Meg\u00edas D.; Paciello M.L.; S\u00e1nchez-Pina J.; P\u00e9rez-Mart\u00ednez A.; Lee D.A.; Powell D.J.; R\u00edo P.; Mart\u00ednez-L\u00f3pez J.; NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J  2021,11(8),146","journal-title":"Blood Cancer J"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"Chu J.","year":"2014","unstructured":"Chu J.; Deng Y.; Benson D.M.; He S.; Hughes T.; Zhang J.; Peng Y.; Mao H.; Yi L.; Ghoshal K.; He X.; Devine S.M.; Zhang X.; Caligiuri M.A.; Hofmeister C.C.; Yu J.; CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia  2014,28(4),917-927","journal-title":"Leukemia"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","volume":"11","author":"Radhakrishnan S.V.","year":"2020","unstructured":"Radhakrishnan S.V.; Luetkens T.; Scherer S.D.; Davis P.; Vander Mause E.R.; Olson M.L.; Yousef S.; Panse J.; Abdiche Y.; Li K.D.; Miles R.R.; Matsui W.; Welm A.L.; Atanackovic D.; CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun  2020,11(1),798","journal-title":"Nat Commun"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"Casucci M.","year":"2013","unstructured":"Casucci M.; Nicolis di Robilant B.; Falcone L.; Camisa B.; Norelli M.; Genovese P.; Gentner B.; Gullotta F.; Ponzoni M.; Bernardi M.; Marcatti M.; Saudemont A.; Bordignon C.; Savoldo B.; Ciceri F.; Naldini L.; Dotti G.; Bonini C.; Bondanza A.; CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood  2013,122(20),3461-3472","journal-title":"Blood"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","volume":"36","author":"O\u2019Neal J.","year":"2022","unstructured":"O\u2019Neal J.; Ritchey J.K.; Cooper M.L.; Niswonger J.; Sof\u00eda Gonz\u00e1lez L.; Street E.; Rettig M.P.; Gladney S.W.; Gehrs L.; Abboud R.; Prior J.L.; Haas G.J.; Jayasinghe R.G.; Ding L.; Ghobadi A.; Vij R.; DiPersio J.F.; CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8 CS1 expressing CAR-T cells. Leukemia  2022,36(6),1625-1634","journal-title":"Leukemia"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Wang Y.","year":"2022","unstructured":"Wang Y.; Cao J.; Gu W.; Shi M.; Lan J.; Yan Z.; Jin L.; Xia J.; Ma S.; Liu Y.; Li H.; Pan B.; Chen W.; Fei X.; Wang C.; Xie X.; Yu L.; Wang G.; Li H.; Jing G.; Cheng H.; Zhu F.; Sun H.; Sang W.; Li D.; Li Z.; Zheng J.; Xu K.; Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol  2022,40(20),2246-2256","journal-title":"J Clin Oncol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","volume":"41","author":"Tang Y.","year":"2022","unstructured":"Tang Y.; Yin H.; Zhao X.; Jin D.; Liang Y.; Xiong T.; Li L.; Tang W.; Zhang J.; Liu M.; Yu Z.; Liu H.; Zang S.; Huang Z.; High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res  2022,41(1),2","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","volume":"108","author":"Garc\u00eda-Guerrero E.","year":"2022","unstructured":"Garc\u00eda-Guerrero E.; Rodr\u00edguez-Lobato L.G.; Sierro-Mart\u00ednez B.; Danhof S.; Bates S.; Frenz S.; H\u00e4rtle L.; G\u00f6tz R.; Sauer M.; Rasche L.; Kort\u00fcm K.M.; P\u00e9rez-Sim\u00f3n J.A.; Einsele H.; Hudecek M.; Prommersberger S.R.; All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica  2022,108(2),568-580","journal-title":"Haematologica"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"Zhang X.","year":"2022","unstructured":"Zhang X.; Zhang C.; Qiao M.; Cheng C.; Tang N.; Lu S.; Sun W.; Xu B.; Cao Y.; Wei X.; Wang Y.; Han W.; Wang H.; Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell  2022,40(11),1407-1422.e7","journal-title":"Cancer Cell"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.tranon.2021.101085","volume":"14","author":"Liu X.","year":"2021","unstructured":"Liu X.; Zhang Y.; Li K.; Liu Y.; Xu J.; Ma J.; An L.; Wang H.; Chu X.; A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma. Transl Oncol  2021,14(7),101085","journal-title":"Transl Oncol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"Zheng W.","year":"2018","unstructured":"Zheng W.; O\u2019Hear C.E.; Alli R.; Basham J.H.; Abdelsamed H.A.; Palmer L.E.; Jones L.L.; Youngblood B.; Geiger T.L.; PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia  2018,32(5),1157-1167","journal-title":"Leukemia"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"Yeku O.O.","year":"2016","unstructured":"Yeku O.O.; Brentjens R.J.; Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans  2016,44(2),412-418","journal-title":"Biochem Soc Trans"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"Zhang X.","year":"2023","unstructured":"Zhang X.; Zhang H.; Lan H.; Wu J.; Xiao Y.; CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol  2023,14,1101495","journal-title":"Front Immunol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","volume":"14","author":"Zhang H.","year":"2021","unstructured":"Zhang H.; Hu Y.; Shao M.; Teng X.; Jiang P.; Wang X.; Wang H.; Cui J.; Yu J.; Liang Z.; Ding L.; Han Y.; Wei J.; Xu Y.; Li X.; Shan W.; Shi J.; Luo Y.; Qian P.; Huang H.; Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. J Hematol Oncol  2021,14(1),113","journal-title":"J Hematol Oncol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"Rafiq S.","year":"2020","unstructured":"Rafiq S.; Hackett C.S.; Brentjens R.J.; Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol  2020,17(3),147-167","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"Yi M.","year":"2018","unstructured":"Yi M.; Jiao D.; Xu H.; Liu Q.; Zhao W.; Han X.; Wu K.; Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer  2018,17(1),129","journal-title":"Mol Cancer"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"Liu H.","year":"2021","unstructured":"Liu H.; Lei W.; Zhang C.; Yang C.; Wei J.; Guo Q.; Guo X.; Chen Z.; Lu Y.; Young K.H.; Lu Z.; Qian W.; CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1\u2013positive B-cell lymphoma. Clin Cancer Res  2021,27(2),473-484","journal-title":"Clin Cancer Res"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","volume":"13","author":"Tomasik J.","year":"2022","unstructured":"Tomasik J.; Jasi\u0144ski M.; Basak G.W.; Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol  2022,13,1034707","journal-title":"Front Immunol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1200\/JCO.2022.40.16_suppl.7522","volume":"40","author":"Kim W.S.","year":"2022","unstructured":"Kim W.S.; Kim S.J.; Yoon S.; Kim J.R.; Phase 1\/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma. J Clin Oncol  2022,40(16_suppl)(Suppl.),7522","journal-title":"J Clin Oncol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.tranon.2021.101070","volume":"14","author":"Moghanloo E.","year":"2021","unstructured":"Moghanloo E.; Mollanoori H.; Talebi M.; Pashangzadeh S.; Faraji F.; Hadjilooei F.; Mahmoodzadeh H.; Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs. Transl Oncol  2021,14(6),101070","journal-title":"Transl Oncol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","volume":"9","author":"Gagelmann N.","year":"2022","unstructured":"Gagelmann N.; Sureda A.; Montoto S.; Murray J.; Bola\u00f1os N.; Kenyon M.; Beksac M.; Sch\u00f6nland S.; Hayden P.; Scheurer H.; Morgan K.; Garderet L.; McLornan D.P.; Ruggeri A.; Access to and affordability of CAR T-cell therapy in multiple myeloma: An EBMT position paper. Lancet Haematol  2022,9(10),e786-e795","journal-title":"Lancet Haematol"},{"key":"ref=147","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221142945","volume":"30","author":"Kapinos K.A.","year":"2023","unstructured":"Kapinos K.A.; Hu E.; Trivedi J.; Geethakumari P.R.; Kansagra A.; Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma. Cancer Contr  2023,30","journal-title":"Cancer Contr"},{"key":"ref=148","first-page":"1228","volume":"91","author":"Lenhoff S.","year":"2006","unstructured":"Lenhoff S.; Hjorth M.; Turesson I.; Westin J.; Gimsing P.; Wisl\u00f6ff F.; Ahlberg L.; Carlson K.; Christiansen I.; Dahl I.M.; Forsberg K.; Brinch L.; Hammerstr\u00f6m J.; Johnsen H.E.; Knudsen L.M.; Linder O.; Mellqvist U.H.; Nesthus I.; Nielsen J.L.; Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica  2006,91(9),1228-1233","journal-title":"Haematologica"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"Munshi N.C.","year":"2017","unstructured":"Munshi N.C.; Avet-Loiseau H.; Rawstron A.C.; Owen R.G.; Child J.A.; Thakurta A.; Sherrington P.; Samur M.K.; Georgieva A.; Anderson K.C.; Gregory W.M.; Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol  2017,3(1),28-35","journal-title":"JAMA Oncol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"Landgren O.","year":"2016","unstructured":"Landgren O.; Devlin S.; Boulad M.; Mailankody S.; Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis. Bone Marrow Transplant  2016,51(12),1565-1568","journal-title":"Bone Marrow Transplant"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00281-018-0696-7","volume":"41","author":"Klausen U.","year":"2019","unstructured":"Klausen U.; J\u00f8rgensen N.G.D.; Grauslund J.H.; Holmstr\u00f6m M.O.; Andersen M.H.; Cancer immune therapy for lymphoid malignancies: Recent advances. Semin Immunopathol  2019,41(1),111-124","journal-title":"Semin Immunopathol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","volume":"129","author":"Rosenblatt J.","year":"2017","unstructured":"Rosenblatt J.; Avigan D.; Targeting the PD-1\/PD-L1 axis in multiple myeloma: A dream or a reality? Blood  2017,129(3),275-279","journal-title":"Blood"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"Chung D.J.","year":"2016","unstructured":"Chung D.J.; Pronschinske K.B.; Shyer J.A.; Sharma S.; Leung S.; Curran S.A.; Lesokhin A.M.; Devlin S.M.; Giralt S.A.; Young J.W.; T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy. Cancer Immunol Res  2016,4(1),61-71","journal-title":"Cancer Immunol Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","volume":"107","author":"Prabhala R.H.","year":"2006","unstructured":"Prabhala R.H.; Neri P.; Bae J.E.; Tassone P.; Shammas M.A.; Allam C.K.; Daley J.F.; Chauhan D.; Blanchard E.; Thatte H.S.; Anderson K.C.; Munshi N.C.; Dysfunctional T regulatory cells in multiple myeloma. Blood  2006,107(1),301-304","journal-title":"Blood"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","volume":"126","author":"Leone P.","year":"2015","unstructured":"Leone P.; Berardi S.; Frassanito M.A.; Ria R.; De Re V.; Cicco S.; Battaglia S.; Ditonno P.; Dammacco F.; Vacca A.; Racanelli V.; Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood  2015,126(12),1443-1451","journal-title":"Blood"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673268932230920063933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221478\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673268932230920063933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:18:23Z","timestamp":1724962703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221478\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":155,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673268932230920063933","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}